T A B L E O F C O N T E N T S
Timely diagnosis of alcoholic cirrhosis in people with alcoholic liver disease is the cornerstone for evaluation of prognosis or choosing treatment strategies.
Objectives
To determine the diagnostic accuracy of ultrasonography for detecting the presence or absence of cirrhosis in people with alcoholic liver disease compared with liver biopsy as reference standard.
To determine the diagnostic accuracy of any of the ultrasonography tests, B-mode or echo-colour Doppler ultrasonography, used singly or combined, or plus ultrasonography signs, or a combination of these, for detecting hepatic cirrhosis in people with alcoholic liver disease compared with liver biopsy as a reference standard, irrespective of sequence.
Search methods
We performed searches in The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Hepato-Biliary Group Diagnostic Test Accuracy Studies Register, The Cochrane Library (Wiley), MEDLINE (OvidSP), EMBASE (OvidSP), and the Science Citation Index Expanded to 8 January 2015. We applied no language limitations.
We screened study references of the retrieved studies to identify other potentially relevant studies for inclusion in the review and read abstract and poster publications.
Selection criteria
Three review authors independently identified studies for possible inclusion in the review. We excluded references not fulfilling the inclusion criteria of the review protocol. We sent e-mails to study authors.
The included studies had to evaluate ultrasound in the diagnosis of hepatic cirrhosis using only liver biopsy as the reference standard.
The maximum time interval of investigation with liver biopsy and ultrasonography should not have exceeded six months. In addition, ultrasonography could have been performed before or after liver biopsy.
Data collection and analysis
We followed the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.
Main results
The review included two studies that provided numerical data regarding alcoholic cirrhosis in 205 men and women with alcoholic liver disease. Although there were no applicability concerns in terms of participant selection, index text, and reference standard, we judged the two studies at high risk of bias. Participants in both studies had undergone both liver biopsy and ultrasonography investigations. The studies shared only a few comparable clinical signs and symptoms (index tests).
We decided to not perform a meta-analysis due to the high risk of bias and the high degree of heterogeneity of the included studies.
Authors' conclusions
As the accuracy of ultrasonography in the two included studies was not informative enough, we could not recommend the use of ultrasonography as a diagnostic tool for liver cirrhosis in people with alcoholic liver disease. In order to be able to answer the review questions, we need diagnostic ultrasonography prospective studies of adequate sample size, enrolling only participants with alcoholic liver disease.
The design and report of the studies should follow the Standards for Reporting of Diagnostic Accuracy. The sonographic features, with validated cut-offs, which may help identify clinical signs used for diagnosis of fibrosis in alcoholic liver disease, should be carefully selected to achieve maximum diagnostic accuracy on ultrasonography.
P L A I N L A N G U A G E S U M M A R Y

Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease
Background
Heavy alcohol consumption causes alcoholic liver disease and may lead to a number of other concomitant diseases. Alcohol may damage the function of body organs and can cause cancer. Liver damage due to excessive alcohol consumption is usually presented as fatty liver (build-up of fats in the liver), steatohepatitis (inflammation of the liver with concurrent fat accumulation in the liver), fibrosis (fibrous degeneration), alcoholic cirrhosis (scarring of the liver), and hepatocellular carcinoma (most common type of liver cancer). When liver fibrosis progresses, alcoholic cirrhosis occurs.
Abstinence from alcohol may help people with alcoholic disease to improve their health at any stage of their disease; however, the more advanced the stage, the higher the risk of complications, co-morbidities (presence of other diseases), and mortality (death), and lesser the effect of abstinence. Abstinence from alcohol one month after diagnosis of early cirrhosis will improve the chance of a seven-year life expectancy by 1.6 times. Liver transplantation (replacement of a diseased liver) is the only radical method that may change the prognosis of a person with alcoholic liver disease; however, besides the difficulties of finding a suitable liver transplant organ, there are many other factors that may influence a person's survival after transplantation.
Ultrasound is an inexpensive method that has been used for years in clinical practice to diagnose alcoholic cirrhosis. Ultrasound parameters for assessing cirrhosis in people with alcoholic liver disease encompass among others liver size, bluntness of the liver edge, coarseness of the liver parenchyma (part of the liver that filters blood to remove toxins), nodularity (unevenness) of the liver surface, size of the lymph nodes (small glands that filter lymph) around the hepatic artery (which supplies oxygenated blood to the liver), irregularity and narrowness of the inferior vena cava (which carries blood from the lower body to the heart), portal vein velocity, and spleen size.
Diagnosis of cirrhosis by ultrasound, especially in people who have no symptoms, may have its advantages for the prognosis, motivation, and treatment of these people to decrease their alcohol consumption or become abstinent.
Timely diagnosis of alcoholic cirrhosis in people with alcoholic liver disease is important for evaluation of prognosis or choosing treatment strategies.
Aim
The primary review aim was to determine the diagnostic accuracy of ultrasound for detecting the presence or absence of cirrhosis in people with alcoholic liver disease compared with liver biopsy (where a small needle is inserted into the liver to collect a sample, which is then examined in a laboratory) as reference standard (i.e., the best available test). The secondary aim of the review was to determine the diagnostic accuracy of any of the ultrasound tests, B-mode (a two-dimensional ultrasound image display composed of bright dots representing the ultrasound echoes) or echo-colour Doppler ultrasound (a colour ultrasound image showing blood flow through the liver), used singly or combined, or plus ultrasound signs, or a combination of these, for detecting hepatic cirrhosis in people with alcoholic liver disease compared with liver biopsy as a reference standard.
Methods
We searched the medical literature to retrieve studies for the review to 8 January 2015.
Results
We identified two studies; one from 1985, performed in France, and the other from 2013, performed in South Korea. We could not analyse the data as the two studies with 205 participants in total were very different and they shared only a few clinical signs and symptoms for assessment of cirrhosis. We considered the studies at high risk of bias (the quality of the evidence was low).
Funding
One of the two studies was sponsored by a grant from the Ministry of Health and Welfare, Republic of Korea.
Conclusions
The review authors cannot recommend the use of ultrasound as a diagnostic tool for liver cirrhosis in people with alcoholic liver disease as the obtained study data were insufficient for analysis. Diagnostic ultrasound prospective studies with a large number of people and similar signs and features on ultrasound imaging are needed to establish how good the test is in detecting cirrhosis in people with alcoholic liver disease.
B A C K G R O U N D
Alcohol consumption is a worldwide problem. Every year approximately 2.5 million people die of it; 320,000 of them are young people between 15 and 29 years of age. Based on estimates for 2004, alcohol was responsible for almost 4% of all deaths in the world (WHO 2010).
Heavy alcohol consumption causes alcoholic liver disease and is a causal factor of many types of liver injuries and concomitant diseases. It is a true systemic disease that may damage the digestive tract, the nervous system, the heart and vascular system, the bone and skeletal muscle system, and the endocrine and immune system, and can lead to cancer (WHO 2010; Rocco 2014) .
Liver damage in turn, can present as multiple alcoholic liver diseases, including fatty liver, steatohepatitis, fibrosis, alcoholic cirrhosis, and hepatocellular carcinoma, with presence or absence of hepatitis B or C virus infection (Brunt 1974; Bruha 2012; Testino 2014) . There are three scarring types (fibrosis) that are most commonly found in alcoholic liver disease: centrilobular scarring, pericellular fibrosis, and periportal fibrosis. When liver fibrosis progresses, alcoholic cirrhosis occurs. Hepatocellular carcinoma occurs in 5% to 15% of people with alcoholic cirrhosis, but people in whom hepatocellular carcinoma has developed are often coinfected with hepatitis B or C virus (MacSween 1986; Jaurigue 2014).
Abstinence from alcohol may help people with alcoholic disease in improving their prognosis of survival at any stage of their disease; however, the more advanced the stage, the higher the risk of complications, co-morbidities, and mortality, and lesser the effect of abstinence (Borowsky 1981) . Being abstinent one month after diagnosis of early cirrhosis will improve the chance of a seven-year life expectancy by 1.6 times (Verrill 2009). Liver transplantation is the only radical method that may change the prognosis of a person with alcoholic liver disease; however, besides the difficulties of finding a suitable liver transplant organ, there are many other factors that may influence a person's survival (Iruzubieta 2013; Singal 2013) .
Cochrane systematic reviews of randomised clinical trials of pharmacological interventions used for reducing alcohol consumption such as acamprosate, benzodiazepines, naltrexone, gamma-hydroxybutyrate, baclofen (derivative of gamma-aminobutyric acid), and anticonvulsants versus placebo or another drug in alcohol-dependent people have studied the benefits and harms of these interventions for alcohol reduction or withdrawal (Amato 2010; Leone 2010; Minozzi 2010; Rösner 2010a; Rösner 2010b; Liu 2013; Pani 2014) . However, the conclusions, despite showing some potential tendency of alcohol reduction or promotion of abstinence, lack the desired robustness of evidence as the performed randomised clinical trials for alcohol withdrawal with the suggested drug interventions may fail in quality, be of insufficient sample size, be too heterogeneous, or lack sufficient evidence for benefits. Without diminishing nutritional and supportive management of people with alcoholic liver disease, complete abstinence from alcohol seems still to be the only recommended form of hepatoprotection.
Ultrasound is an inexpensive method that has been used for years in clinical practice to diagnose alcoholic cirrhosis (Rockey 2009; O'Shea 2010) . Ultrasound parameters for assessing cirrhosis in people with alcoholic liver disease encompass among others liver size, bluntness of the liver edge, coarseness of the liver parenchyma, nodularity of the liver surface, size of the lymph nodes around the hepatic artery, irregularity and narrowness of the inferior vena cava, portal vein velocity, and spleen size (Nishiura 2005).
In a series of 1604 people with alcoholic liver disease diagnosed on liver biopsy or clinically confirmed diagnosis, 608 (38%) people had developed alcoholic cirrhosis (Naveau 1997). Diagnosis of cirrhosis by ultrasound, especially in people who are asymptomatic, may have its advantages for the prognosis, motivation, and treatment of these people to decrease their alcohol consumption or become abstinent (O'Shea 2010).
Timely diagnosis of alcoholic cirrhosis in people with alcoholic liver disease is the cornerstone for evaluation of prognosis or choosing treatment strategies in these people.
Target condition being diagnosed
Cirrhosis in people with alcoholic liver disease
People with alcoholic liver disease are at risk of developing liver fibrosis and cirrhosis. This risk is considered higher in people who are binge drinkers, people with increased serum alanine aminotransferase and aspartate aminotransferase levels, and in people with severe alcohol hepatitis on liver biopsy (Bouchier 1992). Cirrhosis may have symptoms and signs of liver disease, and cirrhosis may vary from one person to another. In general, people with alcoholic liver disease see a doctor when symptoms and signs from the complications of cirrhosis have already developed (O'Shea 2010). Physicians should attempt to motivate people to stop drinking. Indirect evidence of alcohol abuse can be collected through questionnaires about drinking habits, through information received from family members, and through running laboratory tests (O'Shea 2010) . Hepatic fibrosis may develop as a result of weekly alcohol consumption of seven to 13 beverages for women (one beverage = 12 g of alcohol) and 14 to 27 beverages for men over the course of five or more years (Savolainen 1993; Becker 1996) . The risk ratio of progression of fibrosis to cirrhosis increases significantly with a daily consumption of 20 to 40 g of ethanol in women and more than 80 g of ethanol in men (Sherlock 1997; O'Shea 2010) . The liver is the main site of alcohol metabolism acting through two hepatic enzymes, alcohol dehydrogenase and cytochrome P-450 (CYP) 2E1. Increased alcohol intake disrupts metabolic liver function, and, as a result, alcoholic liver disease develops (Stewart 2001) . METAVIR is the most widely used scoring system for interpretation of liver biopsy results based on the stage of fibrosis where F0 indicates no fibrosis, F1 indicates portal fibrous expansion (mild fibrosis), F2 indicates thin fibrous septa emanating from portal triads (significant fibrosis), F3 indicates fibrous septa bridging portal triads and central veins (severe fibrosis), and F4 indicates cirrhosis (Table 1) . Michalak 2003 validated the reproducibility of the METAVIR score using a slightly modified METAVIR score, that is, the portal tract/septal fibrosis score, to investigate the amount of fibrosis and study the influence of centrilobular fibrosis and portal tract/septal fibrosis in alcoholic chronic liver disease. The amount of portal tract/septal fibrosis in people with alcoholic chronic disease was greater than the amount of centrilobular fibrosis in the control group of people with viral chronic hepatitis disease, which suggested that portal tract/septal fibrosis was more frequent in alcoholic chronic liver disease than in viral chronic hepatitis. However, centrilobular fibrosis forms with the advance of fibrosis in cirrhosis. The prognostic value of the METAVIR fibrosis score in alcoholic liver disease still needs to be established (Michalak 2003) . In Table 1 , we have included other widely used systems for classification of fibrosis in people with alcoholic liver disease (Knodell 1981; Desmet 1994; Ishak 1995; Brunt 1999; Kleiner 2005; Haque 2010 ). However, as the focus of our review is on alcoholic cirrhosis alone, for discrepancies in classification of cirrhosis, we refer the readers to the last two rows of the table (shaded).
Index test(s)
Ultrasonography is used in clinical practice for diagnosis of cirrhosis in people with alcoholic liver disease as it allows investigation of the hepatic tissue through the generation of ultrasonic waves. B-mode and Echo-colour Doppler ultrasonography seem to be the most often used methods for diagnosis of cirrhosis. There are some other new ultrasound-based methods, such as ultrasoundbased elastography, acoustic radiation force impulse (ARFI), and supersonic shear imaging. Ultrasonic patterns obtained at ultrasonography investigation in B-mode are usually classified as positive or negative considering signs used in different combinations and defined as indices, for example, parenchymal (liver surface, volume, edge, and texture), extrahepatic (spleen volume, presence of ascites), and vascular (diameter of portal and spleen veins). Hepatic fibrosis produces abnormal echo patterns on ultrasound scanning. Much higher attenuation is observed at examination of the liver of people with steatosis compared to the liver of people with hepatic fibrosis (Bamber 1979; Saverymuttu 1986) . 
Clinical pathway
Alternative test(s)
Different methods to assess liver fibrosis have been developed since 1990. Most of them are aimed at quantifying the elasticity or viscoelasticity of the liver tissue. There are two common elements in every elasticity imaging method: a force or stress is applied on the liver tissue and the obtained mechanical response is measured. ARFI (ACUSON S2000; Siemens Ltd.) is a non-invasive imaging technique that can detect and quantify hepatic fibrosis. The ARFI technology is also called liver ultrasound elastography (Iyo 2009). ARFI imaging is faster than conventional methods as ARFI uses higher frequencies that are comparable to those used in colour 
Rationale
Liver biopsy has so far been considered the standard method for detection of hepatic fibrosis and its staging, using different semiquantitative morphological scores on liver tissue samples with a size of no more than 1 to 2 cm 3 (Table 1) . One advantage of liver biopsy is that it may give diagnostic information for concurrent liver diseases (Poulsen 1979; Ismail 2011) . However, there are a number of disadvantages with liver biopsy. It is invasive, and it may have potential risks to the person such as punctures of abdominal organs and haemorrhage. Liver biopsy can be painful, time-consuming, and stressful for the person (Grant 1999; O'Shea 2010; Ivashkin 2011b) . The risk of haemorrhage and death after a percutaneous liver biopsy is especially higher in people with a platelet count of 60,000 per mm 3 or less (Seeff 2010). Transjugular liver biopsy seems a safer alternative for people with low platelet counts or clotting abnormalities. The small size of the tissue samples, either obtained transcutaneously or via the transjugular route, may also lead to sampling errors. The technical possibilities of the ultrasonography equipment and the individual experience of the investigator performing the ultrasonography are the main factors influencing the precision of the ultrasound examination. Consensus on using ultrasonography as a non-invasive method for diagnosis of cirrhosis in people with alcoholic liver disease seems not to have been established, despite being widely used instead of, or together with, other non-invasive techniques (Shiha 2009). When a person presents with clinical symptoms (e.g., ascites, encephalopathy, oesophageal bleeding) of cirrhosis, neither liver biopsy nor ultrasonography are needed. However, in case of insufficient or unclear expression of clinical signs, a wait-and-see approach, ultrasonography, or other alternative non-invasive tests may be considered before arranging a liver biopsy investigation ( Figure 1 ). As cirrhosis is a main prognostic variable with impact on survival of people with alcoholic liver disease, it is important to detect cirrhosis, assess the risk of complications, and encourage abstinence of drinking alcohol (Leong 2012; Singal 2013; Testino 2014) . This review aimed to meta-analyse data from studies on the diagnosis of cirrhosis in people with alcoholic liver disease and to assess the diagnostic accuracy of ultrasonography in detecting the presence of cirrhosis compared with liver biopsy as reference standard, following Cochrane methodology (SRDTA Handbook). We did not identify any meta-analysis or systematic review on the use of ultrasonography for defining the presence of cirrhosis in people with alcoholic liver disease. A Cochrane systematic diagnostic test accuracy review on ultrasonography in detecting cirrhosis in people with alcoholic liver disease compared with liver biopsy does not exist either. Therefore, we conducted this review.
O B J E C T I V E S
Secondary objectives
To determine the diagnostic accuracy of any of the ultrasonography tests, B-mode or Echo-colour Doppler ultrasonography, used singly or combined, or plus ultrasonography signs, or a combination of these, for detecting hepatic cirrhosis in people with alcoholic liver disease compared with liver biopsy as a reference standard, irrespective of sequence. In case of discrepancies in the results, we planned to explore heterogeneity analysing:
• liver biopsy as the reference standard:
• different grade of inflammation (amount of ongoing inflammation and necrosis) according to the liver biopsy (below two grades compared to two or greater grades of activity);
• different lengths of liver biopsy sample (shorter than 15 mm compared to 15 mm or longer) or number of portal tracts (fewer than six compared to six or more), as reported in the studies;
• percutaneous liver biopsy versus transvenous (transjugular) liver biopsy versus laparoscopic liver biopsy;
• different technical characteristics of the ultrasonography equipment (e.g., different transducers, different wave lengths);
• different skills of the operator as stated by the authors;
• complete abstinent (teetotalers) or non-abstinent study participants (as defined in the included studies).
In addition, we attempted to identify the most accurate ultrasonographic tests and indices for diagnosis of cirrhosis in people with alcoholic liver disease.
M E T H O D S Criteria for considering studies for this review
Types of studies Diagnostic cohort study designs and diagnostic case-control study designs that assessed alcoholic cirrhosis in people with alcoholic liver disease through ultrasonography and liver biopsy, irrespective of language or publication status, or whether data were collected prospectively or retrospectively. We planned to include randomised clinical trials or controlled clinical studies had they fulfilled the inclusion criteria of our review protocol. We included studies published as full paper articles, in the form of abstracts published in conference proceedings, or presented as posters if any of these were identified with the searches. We also considered studies if they had included participants with different aetiologies of liver disease.
Participants
Participants of any sex and ethnic origin, over 16 years old, and diagnosed with alcoholic liver disease, following study authors' statements. The participants could have been hospitalised or managed as outpatients. The diagnosis of alcoholic liver disease in the study participants should have been established based on registered history of excessive alcohol intake of sufficient duration and quantity together with clinical evidence of liver disease expressed with physical signs at examination and followed by laboratory evidence of liver disease. To ascertain the diagnosis of alcoholic liver disease and study the presence or absence of cirrhosis, both ultrasonography and liver biopsy should have been performed, irrespective of the sequence. We planned to also include participants if suspected of having non-alcoholic fatty liver disease, in addition to diagnosed alcoholic liver disease. We did not consider for inclusion people diagnosed with alcoholic liver disease and having a concomitant liver disease such as chronic hepatitis C virus infection, chronic hepatitis B virus infection, autoimmune liver disease, or human immunodeficiency virus (HIV) infection. We extracted data on study participants with alcoholic liver disease alone whenever such data were available in the study report or whenever we could obtain the data required for the review through personal communication with study authors. In the latter case, we disregarded some of the data presented in the publication and used the data provided by the study authors through personal communication.
Index tests
Ultrasonography in any mode. As we expected that study authors would have used different measurements, signs, and combinations of signs for assessment of cirrhosis by ultrasonography with different techniques and mode, we did not specify these here in advance. However, we considered parenchymal, vascular, and extrahepatic ultrasonographic signs as different index tests.
Target conditions
There are five stages of liver fibrosis by METAVIR (Table 1) :
• F0 = no fibrosis;
• F1 = mild fibrosis;
• F2 = significant fibrosis;
• F3 = severe fibrosis;
• F4 = cirrhosis.
The target condition is the presence of cirrhosis in people with alcoholic liver disease, defined using the METAVIR score. Thus, we dichotomised the fibrosis estimated by the METAVIR score as follows: we considered people with a METAVIR score of 
Search methods for identification of studies
We combined electronic searches with reading references of identified studies of possible interest.
Electronic searches
We 
Searching other resources
We also screened references of the retrieved studies to identify other potentially relevant studies for inclusion in our review. We considered extracting data from studies presented in an abstract or poster form, or from grey literature only if data for our review could be found.
Data collection and analysis
We followed the guidelines provided in the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.
Selection of studies
Three review authors (CP, MP, and EL) independently identified studies for possible inclusion in the review. While reading titles or abstracts, or both, of the identified studies, we excluded references with a study design not fulfilling the inclusion criteria of our review protocol. We retrieved the full text of the remaining references. During this second selection stage, we grouped together multiple publications of one study fulfilling the inclusion criteria, and then we screened these publications for complimentary data and we checked them for discrepancies. Whenever we were in doubt, CP, GC, or DN wrote e-mails to study authors.
The studies that we included should have evaluated ultrasound in the diagnosis of hepatic cirrhosis using only liver biopsy as the reference standard.
Data extraction and management
Three review authors (CP, GC, and MP) independently extracted data following the protocol. There were no disagreements between review authors extracting the data. The data needed for the conductance of this systematic review were study origin, year and language of publication, study design, participants' epidemiological and laboratory characteristics, definition of alcoholic liver disease as defined by the authors of the individual studies considered for inclusion, technical failures in undertaking liver biopsy and ultrasonography, cirrhosis estimated by morphological score and ultrasonography, and information related to the QUADAS-2 items for evaluation of the risk of bias of the studies (Whiting 2011). In order to provide data for our analyses, the studies had to provide data that could help us calculate the true positive, false positive, true negative, and false negative diagnostic values of ultrasonography for diagnosing cirrhosis. If information on any of the true positive, false positive, true negative, and false negative diagnostic test values or results were missing, we contacted the authors of the included studies in order to obtain missing information. We also contacted authors if other types of information needed for this review were missing, especially when the publication was in the form of an abstract or poster presentation. We used Excel and Review Manager 5 to add data required for statistical analyses (RevMan 2014).
Assessment of methodological quality
Design flaws in test accuracy studies can produce biased results (Lijmer 1999; Whiting 2004; Rutjes 2006) . In addition, evaluation of study results is quite often impossible due to incomplete reporting (Smidt 2005). To limit the influence of different biases, four review authors (CP, GC, MP, and DN), in pairs or independently of one another, assessed the bias risk of the included diagnostic test accuracy studies, using QUADAS-2 domains (Whiting 2011). A fifth review author (ET) was to act as an arbitrator in case of disagreements between the authors assessing the bias risk of the studies. We contacted study authors if information on methodology was lacking in order to assess correctly the risk of bias of the studies. Appendix 2 shows the adopted items that served the purposes of our review in addressing the participant spectrum, index test, target condition, reference standard, and flow and timing, and which answers also reflect the general quality of the included studies.
We classified studies at low risk of bias if all answers to the signalling questions of the four domains and applicability were positive. We classified the studies at high risk of bias if at least one answer to the signalling questions of the four domains and applicability was either negative or unclear (Jüni 1999; Whiting 2005) . We used tabular and graphical displays to summarise QUADAS-2 assessments.
Statistical analysis and data synthesis
We carried out the analyses following Chapter 10 (Analysing and Presenting Results) of the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy (Macaskill 2010). We used Review Manager 5 software for analyses and plots (RevMan 2014). When we had assembled the majority of our studies, we planned to map the individual index tests or index test indices in the individual studies and on the basis thereof determine which to select for meta-analyses. We built two-by-two tables of ultrasonography performance (true positive, true negative, false positive, false negative) for each primary study and for each index test (ultrasonography mode) and for the pre-defined target condition (cirrhosis). We estimated sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR-), positive and negative predictive values (PPV and NPV) with their 95% confidence intervals (CI). First, we performed a graphical descriptive analysis of the included studies: we reported forest plots (sensitivity and specificity separately, with their 95% CIs) and we planned to provide a graphical presentation of the studies in the receiver operating characteristic (ROC) space (sensitivity plotted against 1 -specificity). Second, we planned to perform a meta-analysis. Where case studies provided dichotomised data using a common cut-off, we planned to use the bivariate model and to provide the estimate of the summary operating point (the point with mean sensitivity and mean specificity). Otherwise, we intended to use the hierarchical summary ROC (HSROC) model and to provide a summary ROC curve (Macaskill 2010). We planned to perform all analyses for each test separately. In case of undetermined ultrasonography results, we planned to follow the intention-to-diagnose approach following which we intended to add uninterpretable test results as false positive or false negatives, depending on the liver biopsy result. In this way, we hoped to avoid potential overestimation of diagnostic test accuracy of ultrasonography (Schuetz 2012). We planned to use the pooled estimates obtained from the fitted models to calculate summary estimates of likelihood ratios. We intended to assess the probability of ultrasonography to rule in or to rule out hepatic cirrhosis by considering the estimates of likelihood ratios. A high LR+ (usually greater than 10) means that there is a large increase in post-test probability, starting from pretest probability. A low LR-(usually lower than 0.1) means that there is a large decrease in post-test probability, starting from pretest probability (Schoenfeld 1999). Likelihood ratio estimates can be used in clinical practice to calculate post-test probabilities for individual people, starting from patient-specific pre-test probabilities. We planned to perform direct and indirect comparisons between the index tests by adding co-variates to the bi-variate or HSROC model (Macaskill 2010). In case of inconsistency of the results obtained through direct and indirect comparisons, we intended to report both results; otherwise, we planned to report one of the results, depending on the availability of comparisons. One review author (GC) planned to perform all statistical analyses using SAS statistical software (SAS Institute Inc., Cary, NC, USA).
Investigations of heterogeneity
We did not expect that the ultrasonographic tests and indices used for diagnosis of cirrhosis in people with alcoholic liver disease would cause additional heterogeneity to those already mentioned in Secondary objectives. Whenever possible, we planned to evaluate the effect of the prespecified sources of heterogeneity on the accuracy estimates by adding some relevant co-variates to the bivariate model (Secondary objectives).
Sensitivity analyses
If possible, depending on number of studies with low risk of bias, we planned to assess the effect of risk of bias of the included studies on the diagnostic accuracy by performing a sensitivity analysis, excluding studies with high or unclear risk of bias, and perform a separate sensitivity analysis excluding unblinded studies.
We classified a study with high risk of bias if judged as high risk of bias or unclear risk of bias in at least one of the domains of QUADAS-2 (Appendix 2). We also planned to perform a sensitivity analysis of studies with data received from study authors.
Assessment of reporting bias
We planned to create a funnel plot to investigate reporting bias visually, using the statistical method suggested by Deeks et al. (Deeks 2005) . Having performed two selections, we found that 17,235 were irrelevant references. Eleven references seemed to fulfil the inclusion criteria. However, we had to exclude eight of these references referring to seven studies, and thus three references describing two studies remained for inclusion in our review. We extracted data for the two-by-two tables from two studies; one published as a full-text article (Richard 1985) , and the other provided individual participant data through personal correspondence, which created a new reference (Moon 2013 Figure 2 shows the reference flow.
R E S U L T S Results of the search
Characteristics of included studies
We have summarised the characteristics of the two included studies in the Characteristics of included studies table.
Study design
The two included studies were prospective cohort single-centre studies (Richard 1985; Moon 2013) 2013) . No participants were suspected of having non-alcoholic fatty liver disease in addition to the alcoholic liver disease they were diagnosed with. The two studies included hospitalised participants of both sexes. The participants' mean age in Richard 1985 was 55.6 years (57.4 years for men and 53.8 years for women), and in Moon 2013, the participants' mean age was 50.5 years (51.1 years for men and 44.0 years for women). The number of participants with alcoholic liver disease in the two studies was 205. Richard 1985 included 128 participants with alcoholic liver disease, out of which 72 had alcoholic cirrhosis on liver biopsy, and Moon 2013 sent us individual participant data on 105 participants with alcoholic liver disease, and among them, 70 had alcoholic cirrhosis. Therefore, there were 142 participants with fibrosis stage F4 (i.e., alcoholic cirrhosis). All of these participants underwent both the index test (ultrasonography) and the reference standard (liver biopsy). The study by Moon 2013 also compared the accuracy of ultrasonography versus transient elastography in terms of the degree of hepatic fibrosis. Richard 1985 did not sufficiently report the definition of the diagnosis of alcoholic liver disease; the study authors wrote that the included participants had been drinking 80 g of alcohol per day for no less than one month before hospitalisation. Moon 2013 provided only general characteristics of the participants with cirrhosis. Richard 1985 performed liver biopsy after ultrasonography in 100/ 128 participants, but they did not specify the time interval. Moon 2013 performed liver biopsy within one day after ultrasonography in 105 of the participants following the individual participant data received by Moon through personal communication.
Liver biopsy morphological scoring systems
Richard 1985 did not describe the morphological scoring systems, and Moon 2013 used METAVIR fibrosis scoring system (F0 to F4).
Grade of inflammation
Moon 2013 did not report the level of inflammation. Richard 1985 reported the presence of steatosis in study participants, but the data reported did not allow us to assess the grade of steatosis or level of inflammation.
Length of liver biopsy specimen and number of portal tracts
Moon 2013 excluded participants with liver biopsy specimen lengths less than 15 mm or less than six portal tracts from the analysis. However, we do not know how many of these excluded participants had alcoholic cirrhosis. Richard 1985 provided no information.
Type of liver biopsy
Richard 1985 used laparoscopic liver biopsy in 62 participants and percutaneous liver biopsy in 38 participants. Moon 2013 did not report this information.
Study information on the index test -ultrasonography
Richard 1985 evaluated the following eight ultrasonography signs in combination and each one individually: volume of the liver, irregular outline, coarse echo patterns, fine bright echo patterns, attenuation of the ultrasound beam, splenomegaly, ascites, and portal hypertension. The ultrasonograph used was real-time ultrasound equipment with a 3.5 MHz convex probe (Toshiba). One operator performed one ultrasonography examination per participant. They used B-mode ultrasonography. Moon 2013 developed an ultrasonographic scoring system (USSS) based on six ultrasonography B-mode and Doppler imaging features, used in clinical practice. These features were liver surface and edge nodularity, parenchyma echogenicity, presence of right lobe atrophy, spleen size, splenic vein diameter, and abnormality of hepatic waveform, to evaluate hepatic cirrhosis. Based on the evaluation of each of the six features (with values of 0, 1, and 2), they produced a total score for prediction of liver cirrhosis. The ultrasonograph used was the Prosound alpha10 (Aloka, Tokyo, Japan), with a 3.5 MHz convex probe. There was one operator who performed all ultrasonography examination to determine the USSS.
Neither study reported follow-up. The common signs used by Richard 1985 and Moon 2013 were irregular outline (which corresponds to liver surface and edge nodularity in Moon 2013) and splenomegaly (which corresponds to spleen size in Moon 2013). However, coarse echo patterns, fine bright echo patterns, and attenuation of the ultrasound beam are three signs unified in one by Moon 2013 and described as parenchyma echogenicity. This is why, we present the signs in separate. Figure 3 and Figure 4 summarise the methodological quality in the included studies. The overall risk of bias of both Moon 2013 and Richard 1985 was high. However, there were no applicability concerns. 
Methodological quality of included studies
Findings
Two studies that provided numerical data regarding alcoholic cirrhosis in men and women with alcoholic liver disease fulfilled the inclusion criteria of our review. We could use the data of 205 participants for our analysis. Although there were no applicability concerns in terms of participants selection, index text, and reference standard, we judged the two studies to be at high risk of bias (low quality of evidence). Our analyses of the data showed that the studies shared only a few comparable clinical signs and symptoms, and the results of the studies were heterogeneous. These were the reasons not to perform a meta-analysis. Participants in both studies had undergone both liver biopsy and ultrasonography investigations. The authors of the two studies presented their results separately for each ultrasonographic feature, as well as combined in an overall sensitivity and specificity. The two studies shared only three of the investigated features (see Summary of findings). A visual comparison of the sensitivity and specificity results showed substantial differences. The specificities obtained by Moon 2013 (from 9% to 31% for six features and 49% overall specificity) were much lower than the obtained specificities by Richard 1985 (from 29% to 96% for eight features and 79% overall specificity). The same was also observed for the three common ultrasonography features reported separately as well as the specificity of the overall ultrasonography results. In general, the ultrasonographic features investigated by Moon 2013 had low specificity and higher sensitivity (90% to 100%, overall sensitivity 94%) than by Richard 1985 (from 4% to 81%, overall sensitivity 81%).
Summary of findings
Review question
What is the accuracy of ultrasonography f or diagnosis of alcoholic cirrhosis in people with alcoholic liver disease?
Population M en and wom en, over 16 years old, and diagnosed with alcoholic liver disease, f ollowing study authors' statem ents
Settings
Participants could have been hospitalised or m anaged as outpatients
Numbers of studies, participants, and participants with the target disease 2 studies (reported in 3 publications); 205 participants contributed with data f or the review analysis, out of which 142 participants with the target disease
Study design
Prospective cohort study design with consecutive participants enrolled
Index tests
Ultrasonography (in B-m ode and Doppler im aging) signs (singly or com bined)
Reference standards Liver biopsy. Laparoscopic liver biopsy and percutaneous liver biopsy. Conclusions: as the accuracy of the listed ultrasonography f eatures in the 2 included studies, singly or as a score, was not suf f iciently inf orm ative, we cannot recom m end the use of ultrasonography as a diagnostic tool f or liver cirrhosis in people with alcoholic liver disease CI: conf idence interval.
Study limitations
* Sim ilar tests evaluated by the two studies are presented in one row in the table with their individual sensitivities and specif icities. As we could not perf orm a m eta-analysis due to the risk of bias and heterogeneity, there were no pooled results. As one of the studies used com bined ultrasound signs (hepatom egaly, irregular outline, coarse echo patterns, f ine bright echo patterns, attenuation of the ultrasound beam , splenom egaly, ascites, portal hypertension) (Richard 1985) , and the other study used them as a score (liver surf ace and edge nodularity, parenchym a echogenicity, spleen size, right lobe atrophy, splenic vein diam eter, hepatic vein wavef orm ) (M oon 2013), we presented their individual sensitivities and specif icities.
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D I S C U S S I O N
Summary of main results
In this review, we aimed to determine the diagnostic accuracy of ultrasonography in B-mode or Doppler imaging for detecting the presence or absence of liver cirrhosis in people with alcoholic liver disease compared with liver biopsy as reference standard, irrespective of sequence. We also attempted to determine the diagnostic accuracy of any of the ultrasonography features. We planned to explore heterogeneity regarding liver biopsy, ultrasonography equipment and indices used, operator skills, or study participants. We included two studies that provided numerical data regarding alcoholic cirrhosis in men and women with alcoholic liver disease. Our review was based on 205 participants. We judged both of these studies at high risk of bias due to flow and timing (Richard 1985; Moon 2013) , and due to participant selection (Moon 2013). Participants in both studies had undergone both liver biopsy and ultrasonography investigations. Data for ultrasonography were not available for one participant in Richard 1985 study, but we could not determine how many participants lacked data on ultrasonography in the Moon 2013 study. A meta-analysis was not possible due to the very low number of studies (i.e., two).
Strengths and weaknesses of the review
Despite that we searched the literature systematically for all published studies on ultrasonography versus liver biopsy for alcoholic cirrhosis in people with alcoholic liver disease and that no one else so far has attempted to systematically collect the evidence on the use of the ultrasonography technique as a first-line diagnostic tool following clinical guidelines, we now should consider these points as weaknesses in title formulation. At the time when we developed our idea for this review, we built it on the assumption that liver fibrosis develops differently due to the different aetiological factors causing the liver injury. Following the research of Verrill and colleagues, being abstinent from alcohol for one month after diagnosis of early cirrhosis will improve the chance of a sevenyear life expectancy by 1.6 times in people with alcoholic liver disease (Verrill 2009). Furthermore, the prevalence of cirrhosis in heavy drinkers is still not well known. The volume of the liver may be affected much more during alcohol abuse, and its dimension, among other ultrasound parameters, would depend on the cause of the liver disease (Richard 1985; O'Shea 2010; Moon 2013) . However, uniform assessment of the extent of liver damage on ultrasonographic image by radiologists is not easy to achieve due to the subjective assessment of a large number of indices and signs. All this can affect the diagnostic accuracy of the ultrasound imaging technique in diagnosing cirrhosis, and this could also have been an obstacle for study investigators to perform studies assessing the diagnostic accuracy of ultrasonography using the same or similar sets of signs and features. Hence, we have chosen to address the diagnostic test accuracy of ultrasonography in only people with alcoholic liver disease. We found only two studies that heterogeneous results and we could not pool the data. We found a number of studies that at first selection fulfilled our inclusion criteria, but we could not separate the data on alcoholic cirrhosis in people with alcoholic liver disease from the data of cirrhosis that was due to various aetiologies of the liver disease. We also found other studies that of ultrasonography for detection of fibrosis, but liver biopsy was not the reference standard. The information provided in the studies and through personal correspondence was not sufficient to fill in lacking knowledge on whether alcoholic cirrhosis can be identified by using signs or combinations of signs on ultrasonography.
Applicability of findings to the review question
Despite the relevance of the review question, we could not present any findings since we only identified two studies.
A U T H O R S ' C O N C L U S I O N S Implications for practice
As the accuracy of the listed ultrasonography features in the two included studies, singly or as a score, was not sufficiently informative, we cannot recommend the use of ultrasonography as a diagnostic tool for liver cirrhosis in people with alcoholic liver disease.
Implications for research
In order to answer the review questions, we need diagnostic ultrasonography prospective studies of adequate sample size, enrolling only participants with alcoholic liver disease. The design and report of the studies should follow the Standards for Reporting of Diagnostic Accuracy (The STARD statement). The sonographic features, with validated cut-off values, which may help to identify hepatic signs used for diagnosis of cirrhosis in alcoholic liver disease should be carefully selected in order to achieve consensus among radiologists and maximum diagnostic accuracy on ultrasonography.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Moon 2013
Study characteristics
Patient sampling
Prospective cohort study.
Patient characteristics and setting
Following the published article Moon 2013, 230 participants (187 men, 43 women; aged (mean ± standard deviation) 50.4 ± 9.5 years) with chronic liver disease; 173 with alcoholic liver disease, and 111 with alcoholic liver cirrhosis Prospectively measured and analysed: age, sex, height, weight, aetiology of cirrhosis, Child class, albumin, total bilirubin, prothrombin time, platelet count, liver stiffness measurement by transient elastography, and 6 ultrasound features (liver surface and edge nodularity, parenchyma echogenicity, right lobe atrophy, spleen size, splenic vein diameter, and hepatic vein waveform) All participants were studied using the 2 non-invasive methods: transient elastography (FibroScan; Echosens, Paris, France) with a 3.5 MHz M probe and ultrasound (Prosound α10; Aloka, Tokyo, Japan) with a 3. F0  F0  F0  F0  F0  F0  F0   F1  F1  F1  F1  F1  F1  F1   F1  F1  F2  F1  F1  F1  F1   F2  F3  F3  F2  F2  F2  F2   F3  F3  F4  F2  F3  F3  F3   F4**  F4  F5  F3  F4  F4  F4   F4**  F4  F6  F4  F4  F4  F4 METAVIR, Knodell, Ishak, Kleiner, Desmet, Brunt, and Batts-Ludvig scoring systems are used to classify fibrosis (and steatosis) due to alcoholic liver disease. For references, please see review text. *Adapted from Goodman 2007. **As the focus of our review is on alcoholic cirrhosis alone, for discrepancies in classification of cirrhosis, we have used the last two rows of the table (shaded).
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